Biohaven Pharmaceuticals CEO on how Nurtec migraine drug punches above its weight

(2:9)

How Biohaven’s experimental obesity drug could prevent muscle loss

(6:36)

Biohaven Pharmaceuticals shares surge after Pfizer agrees to acquire company

(3:47)

OCD Research - Biohaven Pharmaceuticals

(2:28)

Biohaven Pharma CEO: We're looking to end 30-year drought in new migraine prevention drugs

(7:8)

Biohaven CEO on teaming with Khloé Kardashian on new migraine campaign

(2:13)

Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman

(4:2)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

Obsessive-compulsive disorder: Through my eyes

(7:46)

All About Troriluzole

(55:29)

Biosergen advances BSG005 antifungal drug candidate trial

(9:43)

Epilepsy | MOA Animation

(4:53)

Development and Delivery of Pharmaceutical Products (CMC) - MaRS Best Practices

(1:7:46)

MSA and ALS | MOD/MOA Animation

(7:10)

Glutamate Modulation | MOA Animation

(3:28)

TOP 10 BIOTECH JOBS IN HEALTHCARE SECTOR : 10 Roles You Need to Know

(8:40)

Biohaven Pharmaceutical CEO on efforts to prevent migraines with oral CGRP

(2:34)

OCD Research Study - Biohaven Pharmaceuticals

(3:20)

Biohaven CEO says new migraine treatment is a 'game changer for patients'

(6:51)

Pfizer acquires Biohaven Pharmaceutical, is this the biggest for the sector?

(3:36)

Biohaven Pharmaceuticals - KCNQ2 DEE

(11:25)

Biohaven Pharmaceuticals (NYSE: BHVN) Rings The Opening Bell®

(1:12)

Biohaven: Who We Are

(2:31)

Cure SMA and Biohaven Pharmaceuticals Clinical Trial Update Webinar

(39:56)

Biohaven’s OCD Clinical Trial Featured on WCVB NewsCenter 5 in Boston

(2:27)

Pfizer acquires Biohaven for $11.6 billion in cash

(1:13)

What is it like to have OCD? Biohaven Pharmaceuticals

(2:57)

Digital Pharma Innovation Week Keynote with Biohaven Pharmaceuticals CEO Vlad Coric

(30:16)